

The 15th World Congress on Brain Injury

Activity dates: 19 – 22 March 2025

Faculty Disclosures

Dr. Rachel Sayko Adams, Ph.D., MPH

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Miss Elizabeth Anne Ambrose, Master of Public Health, Bachelor of Science Elementary and Special Education

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof Vicki Anne Anderson, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Martina Anto-Ocrah, PhD, MPH, MT(ASCP)

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof. Caroline Arbour, R.N.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. David B. Arciniegas, MD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Charlène Aubinet, MSc

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms Petra Avramovic, B. App. Sci (Speech Pathology)

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Hibah O. Awwad, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof Philippe Azouvi, MD, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Vanessa Bachir, O.D., M.Sc., FAAO

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

A/Prof Ian James Baguley, MBBS PHD FAFRM

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Nazanin Bahraini, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Christine Baugh, PhD, MPH

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Eleonore C Bayen, MD, PhD, Professor of Medicine

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Mark Theodore Bayley, MD, FRCPC

- UHN Toronto Rehabilitation Institute: I receive a stipend from this not-for-profit hospital for my leadership role as medical director
- Program Medical Director- UHN Toronto Rehab Institute as noted above
- Presentation contains healthcare company info: No
- No discussion of unapproved drug or product uses.

Dr Miriam Beauchamp, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Cynthia L Beaulieu, PhD, ABPP-CN

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Simon Beaulieu-Bonneau, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Elise Bogart, CPSP

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Jennifer Bogner, Ph.D., ABPP, FACRM

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Eve Boissonnault, M.D. FRCPC

- AbbVie: Consultant, speaker
- AbbVie: Educational grant
- Ipsen: Consultant, advisory board
- Merz: Consultant, speaker, Advisory board
- Pacira: Consultant
- No discussion of unapproved drug or product uses.

Prof. Carolina Bottari, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Lucia Willadino Braga, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Debra Braunling-McMorrow, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Lisa Brenner, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Benjamin L Brett, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Marie-Michele Briand, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Melissa (Liss) Brunner, Ph.D., MHIthSci (Stroke), BaAppSc (SpPath), CPSP MSPAA

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Tamara Bushnik, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms Philomena Butler, MSW

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Terrence Carolan, MSPT, MBA

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Enrico Castelli, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Elizabeth Castro, B.S.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. John Castro, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Mathilde Paule Chevignard, MD, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Imane Samah Chibane, M.D.

- Merz Pharma Canada Ltd.: Consultant
- Unapproved drug or product uses: Use of migraine pharmacological treatment in post traumatic headache

Dr. Haley Chizuk, PhD, ATC

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Meeryo Christa Choe, MD, FAAN

- Pfizer: PI for clinical trials study
- Unapproved drug or product uses: In the treatment of POTS, FDA-approved treatments are limited - may discuss drugs that can be used in POTS, and the literature supports this, but being a relatively new field of study, FDA approval may not yet be available for these medications.

Dr David Xavier Cifu, MD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Raphael Cinotti, MD, Ph.D.

- VIATRIS: Speaker
- No discussion of unapproved drug or product uses.

Dr. Paul Comper, Ph.D.

- National Hockey League Players' Association: Consultant
- No discussion of unapproved drug or product uses.

Dr. John D. Corrigan, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Louise Crowe, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Bernadette A D'Alonzo, Ph.D., MPH

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Jehane Dagher, MD, FRCPC, FABPMR

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Kristen Dams-O'Connor, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Daniel Daneshvar, M.D., Ph.D.

- National Football League Players Association: Receive funding for research and clinical projects
- StataDx: Options holder and medical advisor
- No discussion of unapproved drug or product uses.

Dr. Jill Daugherty, MPH, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms Katie Davies, Phys

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Louis De Beaumont, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Éleine de Guise, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Chantel T Debert, MD MSc FRCPC

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms. Judy Lynne Dettmer, BSW

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Mrs. Daniëlle Driessen, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Simon Driver, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Joëlle Duchesne, M.Sc.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Catherine Duclos, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Mr Benoit Durand, ...

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Naddley Désiré, Ph.D., C.Psych.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Jason Edwards, D.O.

This faculty member discloses the following financial financial relationships with ineligible companies associated with the content of this activity:

- BrainQ: Industry Sponsored Site Principal Investigator for a study examining neuromodulation for motor recovery after stroke. The study has no relevance to spasticity or to this talk.
- Unapproved drug or product uses: Will be discussing spasticity treatment including current treatments that do not have FDA approval.

Dr Carolyn Ann Emery, PT PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Anna Estraneo, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Sara Etheredge, PT, DPT

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Mary K. Ferraro, PhD, OTR/L

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Karen Foley, PhD, Postgraduate Certificate Healthcare Management

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Mr. Evan Foster, M.HSc.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Elinor Fraser, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Pierre Fremont, MD, PhD

- Abbott Point of Care: Paid participation in TBI Advisory Board on portable TBI diagnosis technology
- No discussion of unapproved drug or product uses.

Dr Isabelle Gagnon, PT, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Judith Gargaro, BSc, MEd

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Christopher C Giza, M.D.

- Concussion In Sport Group, Major League Soccer, National Basketball Association, US Soccer: Advisory Board (uncompensated)
- Highmark Interactive: Stock options
- Medical Network Speakers Bureau: Speaker's bureau
- NBA, NFL-Neurological Care Program, NHL/NHL Player's Association, Los Angeles Lakers, Los Angeles Chargers: Clinical consultant (provide medical care)
- NIH, US Dept of Defense/CDMRP: Research Grants
- UCLA Steve Tisch BrainSPORT Program, Easton Clinic for Brain Health: Unrestricted gifts (Philanthropy)
- Co-founder, Symptom wise
- No discussion of unapproved drug or product uses.

Dr. Joseph T Giacino, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Olivia Gosseries, PH.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- Unapproved drug or product uses: To potentially treat patients with disorders of consciousness

Dr. Brian D Greenwald, MD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Julie Haarbauer-Krupa, PhD, FACRM

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.

- No discussion of unapproved drug or product uses.

Erinn M Hade, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Fatemeh Haghighi, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Mohammad Nadir Haider, MD, Ph.D.

- BlinkCNS Inc/BlinkTBI Inc: I was a part time statistician:
- Oculogica Inc: I was a part time statistician
- No discussion of unapproved drug or product uses.

Dr. Flora Hammond, MD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Robin Hanks, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Ashley D Harris, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Madison Harris, OTD, MA, OTR/L

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Carol Hawley, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Professor Jasmeet Pannu Hayes, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Mrs. Martje Huijben, OT, CPCRT (Certified in the Practice of Cognitive Rehabilitation Therapy)

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Jill Hong Ann Hwang, PhD (Clinical Neuropsychology)

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Cindy Beth Ivanhoe, MD

- Allergan: Speakers Bureau
- Ipsen: Research funds
- Merz: Speakers Bureau
- Revance: Consultant
- Unapproved drug or product uses: Different neurotoxins are used for different indications on and off label. These may be mentioned

Dr. Abhishek Jaywant, Ph.D.

- Axem Neurotechnology Inc.: Consultant
- No discussion of unapproved drug or product uses.

Dr. Barry Jordan, M.D., M.P.H

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Shannon B Juengst, PhD, CRC

- Create Ability Concepts Inc.: I would receive royalties on a license for a measure I developed that is included in their MyBrain app, should they make a profit on it. I have not received any royalties to date. The measure, which is part of my presentation, is freely available for private and research use (I receive no royalties under these circumstances).
- No discussion of unapproved drug or product uses.

Michal Katz-Leurer, PT, MPH, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Karnig Kazazian, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Miss Hope Kent, M.Sc.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Brynna Kerr, M.Sc.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Jessica McKinney Ketchum, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Adam Kinney, PhD, OTR/L

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Robyn S Klein, M.D., Ph.D.

- Merck Manuals: Editor of Neuroinfectious Diseases
- No discussion of unapproved drug or product uses.

Dr. Anthony E Kline, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Ingela Kristiansen, MD, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Maude Laguë-Beauvais, Ph.D./Psy.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Marie-Eve Lamontagne, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Pierre Langevin, PT, Ph.D.

- Atlas Medic: Paid Instructor on concussion for this company that sell health care products
- Clinique Cortex: Employee and co owner of this private practice concussion clinic
- No discussion of unapproved drug or product uses.

Anne-Sophie Langlois, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Jan Lavrijsen, M.D., Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Suzanne Lecerc, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. John Leddy, M.D.

- Neck Care: Scientific Advisory Board
- Zeiss: Consultant
- Minority owner in 360 Concussion Care, a learning health system in Canada
- No discussion of unapproved drug or product uses.

Professor Jan Lexell, MD, Ph.D., D.Phil H.C.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Professor Jonathan Lifshitz, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Mark Linden, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Roberto Llorens, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Mrs Geneviève Léveillé, Bsc erg.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof em. Andrew I.R. Maas, M.D., Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Wendy L. Magee, PhD Music Therapist

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Mr Kit Malia, BEd M.Sc.

- Brain Tree Training: Trainer
- Trainer. Educational provision
- No discussion of unapproved drug or product uses.

Dr. Hana Malá Rytter, M.Sc., Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Geoffrey T. Manley, MD, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Rebekah Mannix, M.D., MPH

- Abbott Laboratories: Grants to my institution
- No discussion of unapproved drug or product uses.

Dr. Géraldine Martens, PT

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Petra Maurer-Karattup, M.S.Psych., Clinical Neuropsychology, Dr. rer. nat. Psych.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Jamie Mayer, Ph.D., CCC-SLP

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Michael McCrea, Ph.D.

- Abbott Laboratories: Research funding to Medical College of Wisconsin
- No discussion of unapproved drug or product uses.

Dr Joshua Patrick McGeown, MSc, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Grainne McGettrick, BS, MA

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Ann Carolyn McKee, MD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof. Michelle McKerral, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Peter Meulenbroek, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Laura Monetta, Orth

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof. Martin M Monti, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- Unapproved drug or product uses: I will disclose at the beginning of my talk my intention to present data from unlabeled use of a low intensity focused ultrasound device.

Dr. Sarah Elizabeth Patricia Munce, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Laura Murray, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Brooke Marie Murtaugh, OTD, OTR/L, CBIST, BT-C

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Lindsay Nelson, Ph.D.

- Resolys Bio, Inc.: Independent consultant
- No discussion of unapproved drug or product uses.

Enrique Noé Sebastián, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms. Katherine A. O'Brien, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Serena Laura Orr, MD, M.Sc., FRCPC

- Cambridge University Press: I receive royalties for book publication
- Unapproved drug or product uses: I will be presenting on pediatric post-traumatic headache management and because there are no FDA approved therapies for this condition, I will discuss off-label treatments. I will indicate this in the presentation.

Dr Marie-Christine Ouellet, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof. Adrian M Owen, PhD, OBE, FRS, FRSC, FCAHS

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Matthew E. Peters, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Caroline Picard, Psy.D

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof Jennie Louise Ponsford, AO, Ph.D.

- Abbott Pharmaceuticals: I will soon receive some funding for assay analysis biomarkers research in TBI studies. This research will not be referred to in my presentations. The funding has not yet been received
- No discussion of unapproved drug or product uses.

Dr. Marie-Julie Potvin, Neuropsychologist

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Mary Jo Pugh, Ph.D., RN

- Sanofi Pharmaceuticals: Research for understanding documentation of ALS in VA Health System Records
- No discussion of unapproved drug or product uses.

Dr. Jana Quinting, Dr.Phil

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Amy E. Ramage, Ph.D., CCC-SLP

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Nick Reed, PhD, MScOT, OT Reg (Ont)

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Rachael Rietdijk, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Angelle M. Sander, Ph.D., FACRM

- National Institute on Disability, Independent Living and Rehabilitation Research: Grant funding
- National Institutes of Health: Grant funding
- No discussion of unapproved drug or product uses.

Dr Ronald C Savage, EdD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms. Myrthe Elisabeth Scheenen, Dr.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Caroline Schnakers, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Andrea Schneider, MD, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Kathryn Schneider, PT, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Proff. Leigh Schrieff-Brown, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Shannon Scratch, Ph.D., C.Psych.

- Canadian Institute of Health Research: Grant holder
- Centre for Leadership, Holland Bloorview Kids Rehab Hospital Foundation: Grant holder
- Mental Health Research Canada: Grant holder
- Patient Centered Outcomes Research Institute: Subgrant holder

- Social Sciences and Humanities Research Council: Grant holder

Dr Ronald Thomas Seel, Ph.D., FACRM

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- Unapproved drug or product uses: Methylphenidate Hydrochloride

Dr. Amy Shapiro-Rosenbaum, Ph.D., ABPP

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Pushpa Sharma, Ph.D

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms. Manju Sharma-Virk, M.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Sandy Shultz, PhD, MSc, BSc.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Jonathan M. Silver, MD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Prof. Grahame K Simpson, MAASW MAPS

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Beth Slomine, Ph.D.

- Cambridge University Press: Royalties for a book
- No discussion of unapproved drug or product uses.

Captain Katherine Price Snedaker, LCSW

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Gilad Sorek, PT, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Professor Dr. Jacoba Margje Spikman, Ph.D., Clinical Neuropsychologist

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Joanne Steel, CPSP

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Mr. Bruce H. Stern, Esq.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Stacy Suskauer, MD

- Myomo: Scientific Advisory Board/stock options
- No discussion of unapproved drug or product uses.

Professor Bonnie Swaine, PT, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Chad Swank, PT, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Mrs. Marjolaine Tapin

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Liliana Teixeira, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr Jacqueline Theis, OD

- Abbvie: Consultant
- Alcon: Speaker/Consultant
- C. Light Technologies: Chief Medical Officer
- Dompe: Speaker Board
- Myze: Advisory Board
- PER: Speaker Board
- Tarsus: Speaker Board
- Vision Science Labs: Advisory Board
- C. Light Technologies - Chief Medical Officer
- No discussion of unapproved drug or product uses.

Dr. Aurore Thibaut, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Professor Leanne Togher, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms. Amanda Tower, B.A.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Laurence Trépanier, B.Sc.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.

- No discussion of unapproved drug or product uses.

Dr Winnie Tso, MBBS, BSc (Hons), MRCPCh, FHKAM (Paediatrics)

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Lyn Turkstra, Ph.D., CCC-SLP, BC-ANCDS

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Gitendra Uswatte, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Eve M. Valera, PhD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Paul Van Donkelaar, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Willemijn Sabien Van Erp, MD Ph.D.

- Bristol Meyers Squibb: Institutional Speaker Fees
- No discussion of unapproved drug or product uses.

Dr. Shari L. Wade, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Brian Waldron, Psy.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Gale G Whiteneck, Ph.D., FACRM

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. John Whyte, MD, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- Unapproved drug or product uses: No psychoactive medications are FDA-approved for cognitive or behavioral intervention in brain injury. I will discuss strong evidence for amantadine and zolpidem in enhancing consciousness after severe brain injury, and single subject methods for assessing the impact of off-label medication trials. I will use generic names.

Dr. Michael W Williams, Ph.D.

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Tricia Williams, PhD., ABPP

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr David Williamson, B. Pharm, Ph. D

- Juno Pharm: Supply for a clinical study
- Unapproved drug or product uses: Dexmedetomidine for TBI-associated agitation

Mrs Rebecca Wolfkiel, MPP

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Keith Owen Yeates, PhD, ABPP, FCAHS, FRSC

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Lauren Zarnett, MD MSc FRCS

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.

- No discussion of unapproved drug or product uses.

Dr. Nathan David Zasler, MD

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Dr. Mariusz Ziejewski, PhD, INZ

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose.
- No discussion of unapproved drug or product uses.

Ms. Anne Brannagan, DIPCOT, MSc, OBE

- Brain Tree Training: Owner
- No discussion of unapproved drug or product uses.